Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.

Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?

Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.

Generation Bio Co. has announced a breakthrough in its nonviral genetic medicine platform with the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA).

The mRNA technology used in vaccines against viral infections could also be developed for cancer therapies. A group of scientists has designed a circular RNA (circRNA) encapsulated in lipid nanoparticles (LNPs) that acts in the mitochondria of tumor cells through the protein gasdermin-D (GSDMD) and reduces adenocarcinoma. The work was published on Oct. 16, 2023, in Nature Cancer.

No one is looking in the rearview mirror at Medtronic plc as a fresh U.S. FDA approval for the next generation version of its intrathecal drug delivery system allows the company to leave behind a spate of problems associated with its Sychromed II device. The device delivers medication directly to the fluid surrounding the spinal cord via a small catheter positioned to deposit the drug at the site of most severe pain. The targeted delivery improves management of chronic and cancer-related pain as well as management of severe spasticity without use of systemic opioids.

Salipro Biotech AB and Icosagen AS have entered into a multitarget antibody research agreement for the discovery and characterization of monoclonal antibodies against several challenging membrane proteins.

Biomap (Beijing) Intelligent Technology Co Ltd. has entered into a strategic collaboration with Sanofi SA to co-develop cutting-edge artificial intelligence (AI) modules for biotherapeutic drug discovery by leveraging Biomap’s AI platform.

Circio Holding ASA and Neoregen Biotech have commenced a research collaboration on novel circular RNA (circRNA) therapeutics based on Circio’s proprietary Circvec technology. The technology is composed of a modular genetic cassette design for efficient biogenesis of multifunctional circRNAs that can be adapted and applied to multiple purposes.

Scientists at the Guangzhou Institutes of Biomedicine and Health have developed a humanized kidney at the mesonephros stage in pig embryos up to day 28 of gestation. It is the first time that this has been achieved in chimeric xenotransplants.